Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...
Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved ...
Pharma presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time ...
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.
Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...
The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
ATTR-CM is a disease in which harmful proteins build up in the heart ... That's more than double the cost of a similar drug ...
Recent health updates include a rise in measles cases in Texas and New Mexico, expansion of Alnylam's heart disease drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback